

14 July 2010

## 2010/11 Multi-product Tender

PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply;
- The draft process and terms and conditions for the Invitation to Tender 2010/11 (2010/11 Tender); and
- Commercial proposals as an alternative to tendering.

PHARMAC welcomes all feedback.

**ALTERNATIVE COMMERCIAL PROPOSAL RESPONSES DUE BY  
5 PM, FRIDAY 13 AUGUST 2010**

**AND ALL OTHER CONSULTATION RESPONSES BY  
5 PM, TUESDAY 24 AUGUST 2010**

Feedback should be provided by submitting an email, fax or letter to:

Kyle Reid  
Tender Analyst  
PHARMAC  
PO Box 10-254  
Wellington 6143

Email: [kyle.reid@pharmac.govt.nz](mailto:kyle.reid@pharmac.govt.nz)

Fax: (04) 460 4995

DDI: (04) 916 7556

All feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and will be considered by the PHARMAC Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

### Details of the proposed 2010/11 Tender

In general, the proposed Tender process would be similar to the 2009/10 Tender. In addition to Alternative Commercial Proposals that are discussed later, we seek comments on the approach outlined in the following pages, in particular on:

- The proposed process;
- The proposed timetable;
- An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft Invitation to Tender (ITT), that you consider would be inappropriate to tender, and the reasons for that view;
- An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft ITT, that you consider should be tendered, and the reasons for that

view. If you wish, you may provide a non-binding confidential indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered;

- Any contractual constraints or patent protection that could restrict PHARMAC from awarding a tender on a particular pharmaceutical;
- For Hospital pharmaceuticals, feedback on the appropriate Discretionary Variance Limit for each pharmaceutical, in the event that a 1% Discretionary Variance Limit is considered clinically unacceptable; and
- Feedback on any unresolved Tender Bid(s) from previous tenders that you consider should remain open for acceptance.

We seek comments on all sections of the draft ITT. The draft ITT is based on the format of the Invitation to Tender dated 4 December 2009 for community supply and/or hospital supply.

### **Alternative Commercial Proposals**

PHARMAC seeks any Alternative Commercial Proposals (ACPs) to tendering that you may wish to submit by **5pm, Friday 13 August 2010**.

An ACP, for example, may offer price reductions on one set of pharmaceuticals in return for PHARMAC agreeing to defer tendering on another group of pharmaceuticals for a period.

Please note the following points with regard to ACPs for both the community and DHB Hospital markets:

- ACPs may include more than one line item and may include pharmaceuticals not listed in Schedule Two of the draft ITT;
- ACPs may seek PHARMAC's agreement to defer tendering or application of reference pricing for a period of time for any pharmaceutical, whether or not it is listed in Schedule Two of the draft ITT;
- ACPs must not involve PHARMAC agreeing to award Sole Subsidised Supply in the community but may include the awarding of Hospital Supply Status for DHB Hospital pharmaceuticals included in Schedule Two;
- PHARMAC reserves the right:
  - not to accept any ACP; and/or
  - not to provide reasons for the acceptance or non-acceptance of any ACP; and/or
  - to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter; and
- PHARMAC may decide not to consider any ACP that is submitted after Friday 13 August 2010.

### **Tender Timelines**

As notified in consultation on the draft ITT in August 2009, this year we are proposing to bring forward the tender timelines by a further month. This would result in the final Invitation to Tender being released in early November 2010 and consequently the closing date for

tender submissions would move forward to late December 2010. The proposed timeline is outlined in the following table:

**Key Dates and Timeframes for the 2010/11 Tender:**

<b>Date</b>	<b>Event</b>
<b>14 July 2010</b>	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
<b>13 August 2010</b>	Final date for receipt of Alternative Commercial Proposals to tendering by PHARMAC.
<b>24 August 2010</b>	Final date for all consultation to be received.
<b>September 2010</b>	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
<b>September 2010</b>	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
<b>September/October 2010</b>	Consultation and Board decisions on Alternative Commercial Proposals.
<b>Early November 2010</b>	Issuing of the 2010/11 Invitation to Tender.
<b>Late December 2010</b>	Invitation to Tender closes.
<b>From January 2011</b>	Board decisions on the first Tender winners announced.

**Draft Invitation to Tender**

PHARMAC seeks feedback on the terms and conditions of the draft ITT, to be considered by the PHARMAC Board at its October 2010 meeting. Attached is the draft list of products to be tendered (Schedule Two).

A complete copy of the draft ITT is available on our website ([www.pharmac.govt.nz](http://www.pharmac.govt.nz)), including the terms of supply. PHARMAC proposes that, if a Tender Bid was accepted by the PHARMAC Board (or the Chief Executive under delegated authority), it would be subject to the terms and conditions of the draft ITT.

The draft ITT is still under development and may change before it is taken to the Board for approval and subsequently issued. At this stage, but depending on the extent of any changes, PHARMAC does not intend to send out any further drafts for consultation.

PHARMAC is seeking feedback on the composition of the draft ITT. Any feedback should be received by PHARMAC no later than **5pm, 24 August 2010**. Late feedback may not be considered. Consultation feedback received by the due date will be presented to the PHARMAC Board for consideration before it makes its decision.

The draft Invitation to Tender comprises the following sections:

Schedule 1: Definitions and interpretation;

Schedule 2: The list of pharmaceuticals proposed to be tendered. Please note that the market data for the year ended 30 June 2010 provided in this Schedule has not yet been finalised; however finalised data would be captured in the final

ITT. The final list of pharmaceuticals would be released as part of the ITT following Board approval (please note that the list may change following consultation, and that you may provide feedback on the inclusion of additional pharmaceuticals after the ITT has been issued, and any such feedback would be considered by the Board (or Chief Executive) before making a final decision on any Tender Bid provided that the feedback is given before the tender close date in late 2010);

- Schedule 3: Tender process (for both hospital and community Tenders);
- Schedule 4: Contract terms for Sole Subsidised Supply and/or Hospital Supply Status;
- Schedule 5: Additional contract terms for Sole Subsidised Supply;
- Schedule 6: Additional contract terms for Hospital Supply Status.

The main changes to the terms and conditions of the draft ITT since last year are:

#### *Lead Time*

PHARMAC proposes to amend the phrase “*market demand*” to “***entire market demand***” in the definition of “Lead Time” in Schedule One of the ITT. This amendment is proposed to reinforce that the tender winning supplier is expected to have sufficient stock on hand to satisfy the total market demand for the relevant Tender Item from the Start Date.

#### *Price Change*

PHARMAC proposes to amend Clause 3.1 of Schedule 5 and Clause 3.1 of Schedule 6. These amendments are intended to ensure that effective price changes are made available to pharmacies by suppliers (via wholesalers, where applicable) on the 12<sup>th</sup> day of the month before the Start Date. We consider that suppliers may need to ensure compliance with this clause by taking steps to manage and/or amend their existing relationships or terms of trade with pharmacies and wholesalers.

PHARMAC recently held a working group involving interested parties to discuss the issues that have been made in recent times around the timing of notification and implementation of price changes in the Pharmaceutical Schedule and the impact on the supply chain. The aim of the working group was to get a better understanding of the different issues and concerns and to consider whether any changes could be made to improve the current system that would meet all interested parties’ needs. This issue was raised by the group and this proposal aims to address concerns raised.

At present, although price changes are effective from the 12<sup>th</sup> of the month, we understand that the effective price to pharmacies may not change until the end of the month. We are, therefore, proposing that suppliers take the necessary steps to ensure that price changes are available to pharmacies from the 12 of the month.

The implementation of this clause would then need to be managed by suppliers with their existing relationships and terms of trade with pharmacies and wholesalers. Suppliers would be free to manage this process in anyway they like and could do so by using credits, bonusing or other arrangements.

More information about the working group and this issue generally can be found on our website.

## Electronic Tender (eTender) system

The final 2010/11 Invitation to Tender will be distributed via PHARMAC's eTender system. Please let us know by **5pm, 30 September 2010** if the contact details for the person responsible for submitting tender bids have changed for your company or if you would like to register your company to use the eTender system.

## Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the ITT dated 23 December 2008 (2008/09 Tender) and the ITT dated 04 December 2009 (2009/10 Tender) prior to issuing the 2010/11 ITT.

Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the 2010/11 ITT is issued in October/November 2010. Unresolved Tender Bids have not been included in the draft pharmaceutical list (Schedule Two). PHARMAC seeks comments from suppliers that consider that any unresolved Tender Bid(s) should remain open for acceptance, by **5pm, 24 August 2010**.

## Products not currently listed on the Pharmaceutical Schedule

The following is a list of chemicals included in draft Schedule Two that are not currently listed on the Pharmaceutical Schedule:

- Eletriptan \*
- Galantamine \*
- Granisetron \*
- Hydrochlorothiazide
- Indomethacin #
- Iron Sucrose
- Levofloxacin \*
- Menadione Sodium Bisulphite #
- Moxifloxacin \*
- Naratriptan \*
- Risedronate Sodium \*
- Rivastigmine \*
- Zolmitriptan \*

We note that funding of the chemicals marked with an "\*" have been considered by the Pharmacology and Therapeutic Advisory Committee (PTAC) or the relevant Subcommittee of PTAC; however further review, and the review of the remainder of the chemicals in the list above may be considered by PTAC and/or PTAC Subcommittee, after tender bids have been received. We note that the chemicals marked with a "#" have been listed on the Pharmaceutical Schedule previously.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Abacavir Sulphate</b>						
Oral liq 20 mg per ml	49,370	\$20,571	\$0.4167	+ C H	1%	
Tab 300 mg	34,977	\$266,991	\$7.6333	+ C H	1%	
<b>Acetazolamide</b>						
Cap modified-release 500 mg				C		Not currently listed on the Pharmaceutical Schedule
<u>Tab 250 mg</u>	374,446	\$38,942	\$0.1040	C H	1%	
<b>Allopurinol</b>						
<u>Tab 100 mg</u>	14,616,421	\$318,053	\$0.0218	C H	1%	A scored tablet is desirable
<u>Tab 300 mg</u>	9,870,823	\$397,794	\$0.0403	C H	1%	
<b>Amantadine Hydrochloride</b>						
<u>Cap 100 mg</u>	541,419	\$431,421	\$0.7968	C H	1%	
<b>Amikacin</b>						
Inj 5 mg per ml, 5 ml				H	1%	
Inj 250 mg per ml, 2 ml				H	1%	
<b>Amiloride</b>						
Tab 5 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Amitriptyline</b>						
Tab 10 mg	15,568,705	\$862,506	\$0.0554	C H	1%	
Tab 25 mg	7,990,479	\$271,676	\$0.0340	C H	1%	
Tab 50 mg	2,232,413	\$116,085	\$0.0520	C H	1%	
<b>Amlodipine</b>						
Tab 2.5 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<u>Tab 5 mg</u>	8,579,632	\$628,887	\$0.0733	C H	1%	
<u>Tab 10 mg</u>	3,726,083	\$439,305	\$0.1179	C H	1%	
<b>Amoxicillin</b>						
<u>Drops 125 mg per 1.25 ml</u>	207,959	\$27,728	\$0.1333	C H	1%	
<u>Inj 250 mg</u>	615	\$764	\$1.2420	C H	1%	
<u>Inj 500 mg</u>	2,870	\$4,087	\$1.4240	C H	1%	
<u>Inj 1 g</u>	6,323	\$13,670	\$2.1620	C H	1%	
<b>Amoxicillin Clavulanate</b>						
<u>Tab amoxicillin 500 mg with potassium clavulanate 125 mg</u>	14,831,550	\$3,722,719	\$0.2510	C H	1%	
<b>Amsacrine</b>						
Inj 75 mg				H PCT	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Anastrozole</b>						
Tab 1 mg	757,583	\$744,957	\$0.9833	C H	1%	
<b>Apomorphine Hydrochloride</b>						
Inj 10 mg per ml, 1 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
Inj 10 mg per ml, 2 ml	7,369	\$162,118	\$22.0000	C H	1%	
<b>Aqueous Cream</b>						
Crm (100 g or less)				H	1%	
<u>Crm (greater than 100 g)</u>	181,350,342	\$826,958	\$0.0046	C H	1%	
<b>Aripiprazole</b>						
Tab 10 mg	227,924	\$938,591	\$4.1180	C H	1%	
Tab 15 mg	52,316	\$305,665	\$5.8427	C H	1%	
Tab 20 mg	37,924	\$269,791	\$7.1140	C H	1%	
Tab 30 mg	19,734	\$171,074	\$8.6690	C H	1%	
<b>Ascorbic Acid</b>						
Eye drops 10%				H	1%	
<b>Aztreonam</b>						
Inj 1 g				H	1%	
<b>Beclomethasone Dipropionate</b>						
Metered aqueous nasal spray, 50 mcg per dose	13,277,359	\$156,009	\$0.0118	* C H	1%	
Metered aqueous nasal spray, 100 mcg per dose	50,778,193	\$624,572	\$0.0123	* C H	1%	
<b>Bendrofluazide</b>						
<u>Tab 2.5 mg</u>	31,207,631	\$473,108	\$0.0152	C H	1%	
<u>Tab 5 mg</u>	3,612,737	\$84,899	\$0.0235	C H	1%	
<b>Benzympenicillin Sodium (Penicillin G)</b>						
<u>Inj 600 mg</u>	8,079	\$8,475	\$1.0490	C H	1%	
<b>Betahistine Dihydrochloride</b>						
Tab 16 mg	1,567,841	\$172,836	\$0.1102	C H	1%	
<b>Betamethasone Valerate</b>						
Crm 0.1%	6,064,207	\$242,568	\$0.0400	C		
Oint 0.1%	1,679,225	\$73,886	\$0.0440	C		
<b>Betaxolol Hydrochloride</b>						
Eye drops 0.25%	41,141	\$97,093	\$2.3600	C		
Eye drops 0.5%	8,715	\$13,073	\$1.5000	C		
<b>Bezafibrate</b>						
<u>Tab 200 mg</u>	1,260,664	\$136,572	\$0.1083	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Bicalutamide</b>							
Tab 50 mg	127,634	\$115,296	\$0.9033	C H	1%		
<b>Brimonidine Tartrate</b>							
Eye Drop 0.15%				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction	
Eye Drops 0.2%	135,885	\$215,514	\$1.5860	C H	1%		
<b>Budesonide</b>							
Cap 3 mg	52,485	\$97,097	\$1.8500	C H	1%	Widening of access, as per PTAC's August 2009 recommendations, may be considered should a tender be awarded	
Metered aqueous nasal spray, 50 mcg per dose	4,853,350	\$57,027	\$0.0118	* C H	1%		
Metered aqueous nasal spray, 100 mcg per dose	29,515,341	\$385,175	\$0.0131	* C H	1%		
<b>Bupivacaine Hydrochloride with Adrenaline</b>							
Inj 0.25% with 1:400,000 of adrenaline, 10 ml				H	1%		
Inj 0.25% with 1:400,000 of adrenaline, 10 ml theatre pack				H	1%		
Inj 0.5% with 1:200,000 of adrenaline, 20 ml				H	1%		
Inj 0.5% with 1:200,000 adrenaline, 20 ml theatre pack				H	1%		
<b>Bupivacaine Hydrochloride with Fentanyl</b>							
Inf 0.125% with 2 mcg fentanyl per ml, 100 ml				H	1%		
Inf 0.125% with 2 mcg fentanyl per ml, 200 ml				H	1%		
Inj 0.125% with 2 mcg fentanyl per ml, 15 ml				H	1%		
Inj 0.125% with 2 mcg fentanyl per ml, 20 ml				H	1%		
<b>Buspiron Hydrochloride</b>							
Tab 5 mg	184,113	\$51,552	\$0.2800	C			
Tab 10 mg	384,932	\$65,438	\$0.1700	C			
<b>Calcipotriol</b>							
Crm 50 mcg per g (pack size 30 g or less)	1,530,238	\$1,030,360	\$0.6733	C H	1%	Volume is aggregated for all pack sizes of calcipotriol cream	
Crm 50 mcg per g (pack size greater than 30 g)	1,530,238	\$1,030,360	\$0.6733	C H	1%	Volume is aggregated for all pack sizes of calcipotriol cream	
Oint 50 mcg per g (pack size 30 g or less)	1,567,007	\$1,055,118	\$0.6733	C H	1%	Volume is aggregated for all pack sizes of calcipotriol ointment	
Oint 50 mcg per g (pack size greater than 30 g)	1,567,007	\$1,055,118	\$0.6733	C H	1%	Volume is aggregated for all pack sizes of calcipotriol ointment	
Soln 50 mcg per ml (pack size 30 ml or less)	293,695	\$197,950	\$0.6740	C H	1%	Volume is aggregated for all pack sizes of calcipotriol solution	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Calcipotriol</b>							
Soln 50 mcg per ml (pack size greater than 30 ml)	293,695	\$197,950	\$0.6740	C H	1%	Volume is aggregated for all pack sizes of calcipotriol solution	
<b>Calcitonin, salmon</b>							
<u>Inj 100 iu per ml, 1 ml</u>	835	\$18,370	\$22.0000	C H	1%		
<b>Calcium Carbonate</b>							
Tab 1.25 g (500 mg elemental) - Tab 1.5 g (600 mg elemental)	36,097,041	\$1,351,302	\$0.0374	C H	1%	The Unit Subsidy reflects the weighted average subsidy of the 1.25 g and 1.5 g tablets	
<u>Tab eff 1.75 g (1 g elemental)</u>	2,492,962	\$543,466	\$0.2180	C H	1%		
<b>Calcium Folate</b>							
Inj 3 mg				H PCT	1%		
<u>Inj 50 mg</u>	350	\$1,715	\$4.9000	C H PCT	1%		
Inj 100 mg				H PCT	1%		
Inj 300 mg				H PCT	1%		
Inj 1 g				H PCT	1%		
Tab 15 mg	2,862	\$18,285	\$6.3890	C H PCT	1%		
<b>Cefazolin Sodium</b>							
<u>Inj 500 mg</u>	2,699	\$2,699	\$1.0000	C H	1%		
<u>Inj 1 g</u>	9,581	\$15,330	\$1.6000	C H	1%		
<b>Cefepime Hydrochloride</b>							
Inj 1 g				H	1%		
Inj 2 g				H	1%		
<b>Cefotaxime</b>							
Inj 500 mg				H	1%		
Inj 1 g				H	1%		
Inj 2 g				H	1%		
<b>Cefoxitin Sodium</b>							
Inj 1 g	10	\$110	\$11.0000	C H	1%		
<b>Ceftazidime</b>							
Inj 250 mg				H	1%		
Inj 500 mg				H	1%		
Inj 1 g				H	1%		
Inj 2 g				H	1%		
<b>Cefuroxime Sodium</b>							
Inj 250 mg				H	1%		
<u>Inj 750 mg</u>	24	\$51	\$2.1420	C H	1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Cefuroxime Sodium</b>						
<u>Inj 1.5 g</u>					H 1%	
<b>Celiprolol</b>						
Tab 200 mg	5,490,429	\$579,545	\$0.1056		C H 1%	
<b>Cetirizine Hydrochloride</b>						
<u>Oral liq 1 mg per ml</u>	4,805,671	\$84,099	\$0.0175		C H 1%	
<u>Tab 10 mg</u>	13,760,766	\$304,113	\$0.0221		C H 1%	
<b>Chlorhexidine Gluconate</b>						
<u>Soln 4%</u>	2,103,737	\$30,294	\$0.0144		C H 1%	
<b>Chlorpheniramine Maleate</b>						
Inj 10 mg per ml					H 1%	
Oral liq 2 mg per 5 ml	10,833,043	\$174,629	\$0.0161		C H 1%	
<b>Ciprofloxacin</b>						
<u>Tab 250 mg</u>	333,622	\$37,254	\$0.1117		C H 1%	
<u>Tab 500 mg</u>	1,541,970	\$251,855	\$0.1633		C H 1%	
<u>Tab 750 mg</u>	33,189	\$8,342	\$0.2513		C H 1%	
<b>Citalopram Hydrobromide</b>						
<u>Tab 20 mg</u>	31,161,839	\$1,402,283	\$0.0450		C H 1%	
<b>Cladribine</b>						
Inj 10 mg					H PCT 1%	
<b>Clarithromycin</b>						
Inj 500 mg					H 1%	
Tab 250 mg	89,706	\$49,659	\$0.5536		C H 1%	
Tab 500 mg	2,820	\$4,693	\$1.6643		C H 1%	
<b>Clotrimazole</b>						
<u>Crm 1%</u>	3,226,732	\$80,668	\$0.0250		C H 1%	
<b>Co-Trimoxazole</b>						
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	3,211,277	\$109,183	\$0.0340		C H 1%	
<b>Cyclizine Hydrochloride</b>						
Oral liq 12.5 mg per 5 ml					C H 1%	Not currently listed on the Pharmaceutical Schedule
<b>Cyclophosphamide</b>						
Inj 1 g					C H PCT 1%	
Inj 2 g					H PCT 1%	
<b>Cyproterone Acetate with Ethinyloestradiol</b>						
<u>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets</u>	9,511,859	\$555,991	\$0.0585		C	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Danazol</b>						
Cap 100 mg	14,848	\$10,146	\$0.6833	C H	1%	
Cap 200 mg	27,023	\$26,438	\$0.9783	C H	1%	
<b>Daunorubicin</b>						
Inj 20 mg				H PCT	1%	
<b>Desmopressin</b>						
Inj 4 mcg per ml, 1 ml	1,468	\$9,862	\$6.7180	C H	1%	
Nasal drops 100 mcg per ml	6,592	\$102,914	\$15.6120	C H	1%	
<u>Nasal spray 10 mcg per dose</u>	78,570	\$392,064	\$4.9900	C H	1%	
<b>Dexamethasone</b>						
Eye oint 0.1%	10,981	\$18,385	\$1.6743	C H	1%	
<b>Dexamethasone with Neomycin and Polymyxin B Sulphate</b>						
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml	133,345	\$120,011	\$0.9000	C		
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g	22,783	\$35,086	\$1.5400	C		
<b>Dextrose</b>						
<u>Inj 50%, 10 ml</u>	11,468	\$52,179	\$4.5500	C H	1%	
Inj 50%, 50 ml				H	1%	
Inj 50%, 90 ml				H	1%	
<b>Diclofenac Sodium</b>						
<u>Eye drops 1 mg per ml</u>	48,221	\$133,090	\$2.7600	C H	1%	
<u>Inj 25 mg per ml, 3 ml</u>	26,309	\$63,142	\$2.4000	C H	1%	
<u>Suppos 12.5 mg</u>	6,743	\$1,247	\$0.1850	C H	1%	
<u>Suppos 25 mg</u>	10,098	\$2,242	\$0.2220	C H	1%	
<u>Suppos 50 mg</u>	74,492	\$28,605	\$0.3840	C H	1%	
<u>Suppos 100 mg</u>	159,727	\$101,586	\$0.6360	C H	1%	
Tab 50 mg dispersible	639,495	\$47,962	\$0.0750 *	C H	1%	
<b>Dipyridamole</b>						
Tab 25 mg	499,654	\$49,727	\$0.0995	C H	1%	
<u>Tab long-acting 150 mg</u>	8,946,562	\$1,717,740	\$0.1920	C H	1%	
Tab long-acting 200 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Disulfiram</b>						
Tab 200 mg	264,376	\$64,243	\$0.2430	C H	1%	
<b>Docetaxel</b>						
Inj 20 mg				H PCT	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>	
<b>Docetaxel</b>						
Inj 80 mg				H PCT	1%	
<b>Docusate Sodium</b>						
<u>Tab 50 mg</u>	557,337	\$22,015	\$0.0395	C H	1%	
<u>Tab 120 mg</u>	1,810,403	\$99,391	\$0.0549	C H	1%	
<b>Domperidone</b>						
Oral liq 1 mg per ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Dothiepin Hydrochloride</b>						
Cap 25 mg	4,232,276	\$201,033	\$0.0475	C		
Tab 75 mg	1,387,326	\$121,391	\$0.0875	C		
<b>Doxazosin Mesylate</b>						
Tab 2 mg	10,378,539	\$474,299	\$0.0457	C H	1%	
Tab 4 mg	9,013,076	\$545,471	\$0.0605	C H	1%	
<b>Doxycycline Hydrochloride</b>						
Tab 50 mg	677,010	\$65,444	\$0.0967 *	C H	1%	
Tab 100 mg	8,150,389	\$264,073	\$0.0324	C H	1%	
<b>Eletriptan</b>						
Tab 20 mg				C		Not currently listed on the Pharmaceutical Schedule
Tab 40 mg				C		Not currently listed on the Pharmaceutical Schedule
Tab 80 mg				C		Not currently listed on the Pharmaceutical Schedule
<b>Emtricitabine</b>						
Cap 200 mg	180,380	\$1,847,091	\$10.2400	C H	1%	
<b>Emulsifying Ointment</b>						
Oint BP (pack size 100 g or less)				H	1%	
<u>Oint BP (pack size greater than 100 g)</u>	52,196,896	\$385,213	\$0.0074	C H	1%	
<b>Ephedrine</b>						
Inj 3 mg per ml, 10 ml prefilled syringe				H	1%	
Inj 30 mg per ml, 1 ml prefilled syringe				H	1%	
<b>Ergometrine Maleate</b>						
Inj 500 mcg per ml, 1 ml	1,255	\$2,912	\$2.3200	C H	1%	
<b>Erythromycin Ethyl Succinate</b>						
<u>Grans for oral liq 200 mg per 5 ml</u>	7,068,282	\$307,470	\$0.0435	C H	1%	
<u>Grans for oral liq 400 mg per 5 ml</u>	4,168,088	\$243,833	\$0.0585	C H	1%	
<b>Erythromycin Lactobionate</b>						
Inj 1 g	283	\$3,093	\$10.9300	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>									
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>			<b>DV Limit</b>	<b>Comments</b>		
<b>Ethinylloestradiol with Levonorgestrel</b>									
Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets	4,707,418	\$370,989	\$0.0788	*	C				
Tab 30 mcg with levonorgestrel 150 mcg	301,611	\$31,693	\$0.1051	*	C				
Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets	29,841,336	\$2,351,781	\$0.0788		C				
<b>Etoposide Phosphate</b>									
Inj 100 mg (of etoposide base)						H PCT	1%		
<b>Exemestane</b>									
Tab 25 mg	161,165	\$142,631	\$0.8850	*	C H		1%	Currently fully funded under Special Authority. Special Authority criteria may be reviewed depending on outcome of Tender	
<b>Filgrastim</b>									
Inj 300 mcg per ml, 0.5 ml						H	1%		
Inj 300 mcg per ml, 1 ml						H	1%		
Inj 480 mcg per ml, 0.5 ml						H	1%		
<b>Finasteride</b>									
<u>Tab 5 mg</u>	554,270	\$354,733	\$0.6400		C H		1%		
<b>Flucloxacillin Sodium</b>									
<u>Inj 250 mg</u>	701	\$631	\$0.9000		C H		1%		
<u>Inj 500 mg</u>	1,691	\$1,759	\$1.0400		C H		1%		
<u>Inj 1 g</u>	19,012	\$26,617	\$1.4000		C H		1%		
<b>Fluconazole</b>									
Oral liq 10 mg per ml						C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction	
<u>Cap 50 mg</u>	102,716	\$25,019	\$0.2436		C H		1%		
<u>Cap 150 mg</u>	48,550	\$63,115	\$1.3000		C H		1%		
<u>Cap 200 mg</u>	38,399	\$26,125	\$0.6804		C H		1%		
<b>Fludarabine Phosphate</b>									
<u>Inj 50 mg</u>						H PCT	1%		
<u>Tab 10 mg</u>						H PCT	1%		
<b>Flumetasone Pivalate</b>									
Ear drops 0.02% with clioquinol 1%	254,520	\$151,355	\$0.5947		C				
<b>Foscarnet</b>									
Inj 24 mg per ml						H	1%		
<b>Fusidic Acid</b>									
Eye drops 1%	189,650	\$170,685	\$0.9000	*	C H		1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Galantamine</b>							
Cap 8 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
Cap 16 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
Cap 24 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
<b>Gliclazide</b>							
<u>Tab 80 mg</u>	21,547,405	\$958,429	\$0.0445		C H 1%		
<b>Glipizide</b>							
<u>Tab 5 mg</u>	14,022,683	\$490,794	\$0.0350		C H 1%		
<b>Glycerol</b>							
Suppos 3 g or less					C H 1%	Not currently listed on the Pharmaceutical Schedule	
<b>Glyceryl Trinitrate</b>							
<u>Spray 400 mcg per dose</u>	30,873,540	\$637,230	\$0.0206		C H 1%		
<u>Tab 600 mcg</u>	79,940	\$6,395	\$0.0800		C H 1%		
<u>TDDS 5 mg</u>	170,357	\$94,037	\$0.5520		C H 1%		
<u>TDDS 10 mg</u>	60,104	\$39,268	\$0.6533		C H 1%		
<b>Granisetron</b>							
Tab 1 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction	
<b>Heparinised Saline</b>							
Inj 100 iu per ml, 5 ml					H 1%		
Inj 100 iu per ml, 2 ml					H 1%		
<b>Homatropine Hydrobromide</b>							
Eye drops 2%	264	\$126	\$0.4787		C		
<b>Hydrochlorothiazide</b>							
Tab 12.5 mg					C	Not currently listed on the Pharmaceutical Schedule	
Tab 25 mg					C	Not currently listed on the Pharmaceutical Schedule	
<b>Hydrocortisone</b>							
Crn 1% (pack size greater than 15 g and less than 100 g)	19,011,652	\$463,884	\$0.0244		C H 1%	Volume is aggregated for all pack sizes of hydrocortisone cream	
<u>Crn 1% (pack size greater than 100 g)</u>	19,011,652	\$463,884	\$0.0244		C H 1%	Volume is aggregated for all pack sizes of hydrocortisone cream	
<u>Powder</u>	60,000	\$79,200	\$1.3200		C H 1%		
<b>Hydrocortisone with Wool Fat and Mineral oil</b>							
<u>Lotn 1% with wool fat hydrous 3% and mineral oil</u>	10,796,484	\$429,700	\$0.0398		C		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Hyoscine N-Butylbromide</b>						
<u>Inj 20 mg, 1 ml</u>	68,255	\$109,754	\$1.6080	C H	1%	
<u>Tab 10 mg</u>	3,668,092	\$297,115	\$0.0810	C H	1%	
<b>Hypromellose</b>						
Eye drops 0.3%	1,461,212	\$255,225	\$0.1747	C H	1%	
<u>Eye drops 0.5%</u>	125,704	\$16,761	\$0.1333	C H	1%	
<b>Ibuprofen</b>						
<u>Tab 200 mg</u>	33,303,238	\$532,852	\$0.0160	C H	1%	
Tab 400 mg	1,014,864	\$36,197	\$0.0357 *	C H	1%	
Tab long-acting 800 mg	2,325,037	\$116,252	\$0.0500 *	C H	1%	
<b>Imipenem with Cilastatin</b>						
Inj 500 mg with cilastatin 500 mg				H	1%	
<b>Imiquimod</b>						
Crm 5%	232,469	\$2,138,715	\$9.2000	C H	1%	
<b>Indomethacin</b>						
Cap 25 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Cap 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Cap long-acting 75 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Intra-Uterine Device</b>						
IUD	7,666	\$302,807	\$39.5000	C		
<b>Iron Polymaltose</b>						
<u>Inj 50 mg per ml, 2 ml</u>	23,786	\$99,663	\$4.1900	C H	1%	
<b>Iron Sucrose</b>						
Inj 20 mg per ml				H	1%	
<b>Isosorbide Mononitrate</b>						
Tab 20 mg	668,337	\$120,301	\$0.1800	C H	1%	
Tab long-acting 40 mg	822,967	\$407,094	\$0.4947	C H	1%	
Tab long-acting 60 mg	11,604,745	\$535,108	\$0.0461	C H	1%	
<b>Ketoconazole</b>						
<u>Shampoo 2%</u>	3,731,179	\$129,845	\$0.0348	C H	1%	
<b>Ketoprofen</b>						
Cap long-acting 100 mg	119,474	\$8,029	\$0.0672 *	C		
Cap long-acting 200 mg	123,773	\$16,635	\$0.1344 *	C		
<b>Labetalol</b>						
Tab 50 mg	228,350	\$19,775	\$0.0866	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Labetalol</b>						
Tab 100 mg	809,800	\$85,758	\$0.1059	C H	1%	
Tab 200 mg	833,172	\$153,887	\$0.1847	C H	1%	
Tab 400 mg	99,859	\$34,391	\$0.3444	C H	1%	
<b>Lamivudine</b>						
Tab 100 mg	298,036	\$1,522,112	\$5.1071	+ C H	1%	
<b>Levofloxacin</b>						
Tab 500 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
<b>Lignocaine</b>						
Topical soln 4%				H	1%	
<b>Lithium Carbonate</b>						
Cap 250 mg	2,131,707	\$164,781	\$0.0773	C H	1%	
Tab long-acting 400 mg	1,287,266	\$227,202	\$0.1765	C H	1%	
<b>Lodoxamide Trometamol</b>						
Eye drops 0.1%	224,871	\$195,863	\$0.8710	C		
<b>Lomustine</b>						
Cap 10 mg				H PCT	1%	
Cap 40 mg				H PCT	1%	
<b>Lorazepam</b>						
Inj 4 mg per ml, 1 ml				H	1%	
<b>Losartan</b>						
Tab 12.5 mg - Tab 25 mg	2,049,769	\$1,269,702	\$0.6194	C H	1%	The Unit Subsidy reflects the weighted average subsidy of the 12.5 mg and 25 mg tablets. Scoring of a 25 mg tablet is desirable
Tab 50 mg	2,848,279	\$2,193,175	\$0.7700	C H	1%	
Tab 100 mg	578,471	\$682,596	\$1.1800	C H	1%	
<b>Losartan with Hydrochlorothiazide</b>						
Tab 50 mg with hydrochlorothiazide 12.5 mg	1,080,212	\$1,080,212	\$1.0000	C H	1%	
<b>Macrogol 3350</b>						
Powder, 6.536 g, sachets				C H	1%	Not currently listed on the Pharmaceutical Schedule
Powder 13.125 g, sachets	1,108,624	\$670,348	\$0.6047	C H	1%	A confidential rebate currently exists
<b>Magnesium Sulphate</b>						
Inj 49.3%, 5 ml				H	1%	
<b>Mebendazole</b>						
Oral liq 100 mg per 5 ml	47,082	\$6,843	\$0.1453	* C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Mebendazole</b>						
<u>Tab 100 mg</u>	31,675	\$22,806	\$0.7200	C H	1%	
<b>Mebeverine Hydrochloride</b>						
<u>Tab 135 mg</u>	1,000,774	\$200,155	\$0.2000	C H	1%	
<b>Mefenamic Acid</b>						
Cap 250 mg	399,937	\$9,998	\$0.0250 *	C H	1%	
<b>Melphalan</b>						
Inj 50 mg				H PCT	1%	
Tab 2 mg	12,437	\$15,576	\$1.2524	C H PCT	1%	
<b>Menadione Sodium Bisulphite</b>						
Tab 10 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Meropenem</b>						
Inj 500 mg				H	1%	
Inj 1 g				H	1%	
<b>Mesalazine</b>						
Suppos 500 mg	131,000	\$165,060	\$1.2600	C H	1%	
Suppos 1 g	77,922	\$141,818	\$1.8200	C H	1%	
<b>Methotrexate</b>						
<u>Inj 100 mg per ml, 10 ml</u>	3,221	\$88,578	\$27.5000	C H PCT	1%	
<u>Inj 100 mg per ml, 50 ml</u>				H PCT	1%	
<b>Methyldopa</b>						
<u>Tab 125 mg</u>	118,270	\$14,192	\$0.1200	C H	1%	
<u>Tab 250 mg</u>	531,176	\$69,584	\$0.1310	C H	1%	
<u>Tab 500 mg</u>	127,902	\$26,668	\$0.2085	C H	1%	
<b>Metoclopramide Hydrochloride</b>						
<u>Inj 5 mg per ml, 2 ml</u>	191,218	\$86,048	\$0.4500	C H	1%	
Oral liq 5 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Metronidazole</b>						
Inj 500 mg, 100 ml				H	1%	
Tab 200 mg	347,467	\$33,009	\$0.0950	C H	1%	
Tab 400 mg	1,292,449	\$226,179	\$0.1750	C H	1%	
Vaginal gel 0.75%				C		Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
<b>Miconazole Nitrate</b>						
<u>Crn 2%</u>	1,685,309	\$47,189	\$0.0280	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Midazolam</b>						
Tab 7.5 mg	334,576	\$34,729	\$0.1038	C H	1%	
<b>Morphine Sulphate</b>						
Inj 1 mg per ml, 10 ml prefilled syringe				H	1%	
Inj 1 mg per ml, 30 ml prefilled syringe				H	1%	
Inj 1 mg per ml, 50 ml prefilled syringe				H	1%	
Inj 2 mg per ml, 30 ml prefilled syringe				H	1%	
<u>Inj 10 mg per ml 1 ml</u>	160,829	\$144,746	\$0.9000	C H	1%	
<u>Inj 30 mg per ml 1 ml</u>	61,266	\$61,021	\$0.9960	C H	1%	
<b>Moxifloxacin</b>						
Inf 400 mg, 250 ml				H	1%	
Tab 400 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
<b>Naphazoline Hydrochloride</b>						
Eye drops 0.1%	104,686	\$28,963	\$0.2767	C H	1%	
<b>Naratriptan</b>						
Tab 2.5 mg				C		Not currently listed on the Pharmaceutical Schedule
<b>Neostigmine</b>						
Inj 2.5 mg per ml, 1 ml	26,708	\$10,843	\$0.4060	C H	1%	
<b>Nicotinic Acid</b>						
Tab 50 mg	1,342,726	\$68,210	\$0.0508	C		
Tab 500 mg	1,002,157	\$176,380	\$0.1760	C		
Tab modified-release 375 mg				C		Not currently listed on the Pharmaceutical Schedule
Tab modified-release 500 mg				C		Not currently listed on the Pharmaceutical Schedule
Tab modified-release 750 mg				C		Not currently listed on the Pharmaceutical Schedule
Tab modified-release 1 g				C		Not currently listed on the Pharmaceutical Schedule
<b>Nifedipine</b>						
Tab long-acting 30 mg	526,321	\$187,721	\$0.3567	C H	1%	
Tab long-acting 60 mg	220,385	\$112,764	\$0.5117	C H	1%	
<b>Nitrofurantoin</b>						
Oral liq 25 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 50 mg	1,657,702	\$296,729	\$0.1790	C H	1%	
Tab 100 mg	464,496	\$140,510	\$0.3025	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Noradrenaline Acid Tartrate</b>						
Inj 1 mg per ml, 2 ml					H 1%	
<b>Norethisterone</b>						
<u>Tab 5 mg</u>	1,443,996	\$360,999	\$0.2500		C H 1%	
<b>Norfloxacilin</b>						
Tab 400 mg	999,578	\$224,905	\$0.2250		C H 1%	
<b>Nortriptyline hydrochloride</b>						
Oral liq 10 mg per 5 ml					C H 1%	Not currently listed on the Pharmaceutical Schedule
<u>Tab 10 mg</u>	5,331,067	\$316,665	\$0.0594		C H 1%	
<u>Tab 25 mg</u>	7,589,744	\$608,866	\$0.0802		C H 1%	
<b>Nystatin</b>						
<u>Oral liq 100,000 u per ml</u>	1,315,947	\$174,911	\$0.1329		C H 1%	
<b>Octreotide (somatostatin analogue)</b>						
<u>Inj 50 mcg per ml, 1 ml</u>	1,879	\$16,347	\$8.7000		C H 1%	
<u>Inj 100 mcg per ml, 1 ml</u>	3,691	\$59,794	\$16.2000		C H 1%	
<u>Inj 500 mcg per ml, 1 ml</u>	1,736	\$138,533	\$79.8000		C H 1%	
LAR inj 10 mg	197	\$349,183	\$1,772.5000		C H 1%	
LAR inj 20 mg	1,195	\$2,818,706	\$2,358.7500		C H 1%	
LAR inj 30 mg	750	\$2,213,438	\$2,951.2500		C H 1%	
<b>Omeprazole</b>						
Inf 40 mg					H 1%	
<u>Inj 40 mg</u>	2,140	\$16,350	\$7.6400		C H 1%	All proton pump inhibitor injections are considered as one Tender Item
<u>Cap 10 mg</u>	4,220,105	\$301,034	\$0.0713		C H 1%	
<u>Cap 20 mg</u>	68,024,760	\$6,923,949	\$0.1018		C H 1%	
<u>Cap 40 mg</u>	16,842,018	\$2,015,428	\$0.1197		C H 1%	
<b>Orphenadrine Citrate</b>						
Tab 100 mg	1,633,921	\$302,929	\$0.1854		C H 1%	
<b>Oxazepam</b>						
Tab 10 mg	918,230	\$18,181	\$0.0198	*	C	
Tab 15 mg	325,395	\$7,972	\$0.0245	*	C	
<b>Oxycodone Hydrochloride</b>						
Cap 5 mg	1,573,896	\$222,706	\$0.1415		+ C H 1%	
Cap 10 mg	1,022,406	\$285,251	\$0.2790		+ C H 1%	
Cap 20 mg	459,968	\$224,694	\$0.4885		+ C H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Oxycodone Hydrochloride</b>						
Inj 10 mg per ml, 1 ml	27,787	\$80,027	\$2.8800	+ C H	1%	
Inj 10 mg per ml, 2 ml	31,523	\$181,572	\$5.7600	+ C H	1%	
Oral liq 5 mg per 5 ml	1,015,291	\$45,485	\$0.0448	+ C H	1%	
Tab controlled-release 5 mg	958,352	\$359,861	\$0.3755	+ C H	1%	
Tab controlled-release 10 mg	2,041,125	\$1,136,907	\$0.5570	+ C H	1%	
Tab controlled-release 20 mg	1,276,643	\$1,208,343	\$0.9465	+ C H	1%	
Tab controlled-release 40 mg	406,484	\$676,593	\$1.6645	+ C H	1%	
Tab controlled-release 80 mg	184,060	\$534,050	\$2.9015	+ C H	1%	
<b>Paclitaxel</b>						
Inj 30 mg					H PCT	1%
Inj 100 mg					H PCT	1%
Inj 150 mg					H PCT	1%
Inj 300 mg					H PCT	1%
Inj 600 mg					H PCT	1%
<b>Pamidronate Disodium</b>						
<u>Inj 3 mg per ml, 5 ml</u>	3	\$56	\$18.7500	C H	1%	
<u>Inj 3 mg per ml, 10 ml</u>	2,220	\$83,250	\$37.5000	C H	1%	
<u>Inj 6 mg per ml, 10 ml</u>	94	\$7,050	\$75.0000	C H	1%	
<u>Inj 9 mg per ml, 10 ml</u>	303	\$34,088	\$112.5000	C H	1%	
<b>Pantoprazole</b>						
<u>Inj 40 mg</u>	180	\$1,575	\$8.7500	C H	1%	All proton pump inhibitor injections are considered as one Tender Item
<b>Paracetamol</b>						
Inj 10 mg per ml, 50 ml					H	1%
<u>Oral liq 120 mg per 5 ml</u>	118,477,754	\$805,649	\$0.0068	C H	20%	
<u>Oral liq 250 mg per 5 ml</u>	143,609,706	\$1,005,268	\$0.0070	C H	20%	
<u>Tab 500 mg</u>	253,914,917	\$2,437,583	\$0.0096	C H	1%	
<b>Paracetamol with Codeine</b>						
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	39,173,467	\$959,750	\$0.0245	C H	1%	
<b>Penicillamine</b>						
Tab 125 mg	19,924	\$12,339	\$0.6193	C H	1%	
Tab 250 mg	53,832	\$53,283	\$0.9898	C H	1%	
<b>Pergolide</b>						
<u>Tab 0.25 mg</u>	90,790	\$43,579	\$0.4800	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Pergolide</b>						
<u>Tab 1 mg</u>	28,107	\$47,782	\$1.7000	C H	1%	
<b>Permethrin</b>						
<u>Crm or lotn 5%</u>	2,694,545	\$327,836	\$0.1217	C H	1%	
<b>Pethidine Hydrochloride</b>						
Inj 50 mg per ml, 1 ml	14,248	\$14,818	\$1.0400	C H	1%	
Inj 50 mg per ml, 1.5 ml	12	\$10	\$0.8700	C H	1%	
Inj 50 mg per ml, 2 ml	51,911	\$57,102	\$1.1000	C H	1%	
<b>Phenobarbitone</b>						
Oral liq 15 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Phytomenadione</b>						
Tab 10 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Pilocarpine</b>						
Eye drops 2% single dose	442	\$706	\$1.5975 *	C H	1%	
<b>Piroxicam</b>						
Tab dispersible 10 mg	58,948	\$3,832	\$0.0650	C H	1%	
Tab dispersible 20 mg	359,016	\$19,746	\$0.0550	C H	1%	
<b>Poloxamer</b>						
<u>Oral drops 10%</u>	251,926	\$31,743	\$0.1260	C H	1%	
<b>Polyvinyl Alcohol</b>						
<u>Eye drops 1.4%</u>	362,849	\$64,829	\$0.1787	C		
Eye drops 1.4% Preservative free				C		Not currently listed on the Pharmaceutical Schedule
<u>Eye drops 3%</u>	110,354	\$27,589	\$0.2500	C		
<b>Potassium Bicarbonate</b>						
Tab 315 mg with sodium acid phosphate 1.937 g and	83,769	\$69,109	\$0.8250	C		
<b>Pravastatin</b>						
Tab 10 mg	2,613	\$2,392	\$0.9153	C H	1%	
Tab 20 mg	10,042	\$14,253	\$1.4193	C H	1%	
Tab 40 mg	9,319	\$20,287	\$2.1770	C H	1%	
Tab 80 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Procaine Penicillin</b>						
<u>Inj 1.5 mega u</u>	3,214	\$32,693	\$10.1720	C H	1%	
<b>Prochlorperazine</b>						
Tab 5 mg	3,923,694	\$132,228	\$0.0337	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Promethazine Hydrochloride</b>						
<u>Tab 10 mg</u>	1,334,503	\$72,597	\$0.0544	C H	1%	
<u>Tab 25 mg</u>	1,277,457	\$113,438	\$0.0888	C H	1%	
<b>Propranolol</b>						
Cap long-acting 160 mg	656,699	\$110,982	\$0.1690	C H	1%	
Tab 10 mg	2,042,631	\$72,513	\$0.0355	C H	1%	
Tab 40 mg	2,264,151	\$105,283	\$0.0465	C H	1%	
<b>Pyridostigmine Bromide</b>						
Tab 60 mg	428,724	\$171,833	\$0.4008	C H	1%	
<b>Quinapril</b>						
<u>Tab 5 mg</u>	10,071,362	\$537,139	\$0.0533	C H	1%	
<u>Tab 10 mg</u>	14,562,813	\$849,497	\$0.0583	C H	1%	
<u>Tab 20 mg</u>	20,898,166	\$1,637,023	\$0.0783	C H	1%	
<b>Quinapril with Hydrochlorothiazide</b>						
<u>Tab 10 mg with hydrochlorothiazide 12.5 mg</u>	2,623,940	\$294,756	\$0.1123	C H	1%	
<u>Tab 20 mg with hydrochlorothiazide 12.5 mg</u>	7,081,158	\$1,078,696	\$0.1523	C H	1%	
<b>Ranitidine Hydrochloride</b>						
Inj 25 mg per ml, 2 ml	2,929	\$5,126	\$1.7500	C H	1%	
Oral liq 150 mg per 10 ml	1,805,736	\$47,852	\$0.0265	C H	1%	
Tab 150 mg	6,700,260	\$214,140	\$0.0320	C H	1%	
Tab 300 mg	2,150,288	\$94,097	\$0.0438	C H	1%	
<b>Risedronate Sodium</b>						
Tab 5 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 30 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 35 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 150 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Rivastigmine</b>						
Cap 1.5 mg				C		Not currently listed on the Pharmaceutical Schedule
Cap 3 mg				C		Not currently listed on the Pharmaceutical Schedule
Cap 4.5 mg				C		Not currently listed on the Pharmaceutical Schedule
Cap 6 mg				C		Not currently listed on the Pharmaceutical Schedule
<b>Rizatriptan</b>						
Tab 5 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Rizatriptan</b>						
Tab 10 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule
Wafer 10 mg	344,105	\$2,904,246	\$8.4400		C H 1%	
<b>Simvastatin</b>						
<u>Tab 10 mg</u>	10,863,104	\$247,437	\$0.0228		C H 1%	
<u>Tab 20 mg</u>	51,954,162	\$1,731,805	\$0.0333		C H 1%	
<u>Tab 40 mg</u>	47,826,783	\$2,843,037	\$0.0594		C H 1%	
<u>Tab 80 mg</u>	5,131,160	\$664,200	\$0.1294		C H 1%	
<b>Sodium Chloride</b>						
Soln 0.9% for irrigation, 30 ml					H 1%	
<b>Sodium Hyaluronate</b>						
Inj 10 mg per ml, 0.35 ml; and inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.4 ml					H 1%	
Inj 10 mg per ml, 0.5 ml; and inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.55 ml					H 1%	
<b>Streptokinase</b>						
Inj 250,000 IU					H 1%	
Inj 1,500,000 IU					H 1%	
<b>Sulindac</b>						
Tab 100 mg	76,420	\$4,066	\$0.0532	*	C	
Tab 200 mg	116,557	\$7,833	\$0.0672	*	C	
<b>Tamoxifen Citrate</b>						
Tab 10 mg	45,573	\$4,922	\$0.1080		C H 1%	
Tab 20 mg	1,485,102	\$164,846	\$0.1110		C H 1%	
<b>Tar with triethanolamine lauryl sulphate and fluorescein</b>						
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>	46,332,344	\$268,728	\$0.0058		C H 1%	
<b>Temazepam</b>						
<u>Tab 10 mg</u>	3,972,184	\$131,877	\$0.0332		C H 1%	
<b>Terbinafine</b>						
<u>Tab 250 mg</u>	1,773,001	\$452,115	\$0.2550		C H 1%	
<b>Testosterone</b>						
Transdermal patch 2.5 mg per day	117,469	\$156,625	\$1.3333		C H 1%	
<b>Testosterone Cypionate</b>						
<u>Inj long-acting 100 mg per ml, 10 ml</u>	609	\$37,399	\$61.4100		C H 1%	
<b>Tetracosactrin</b>						
<u>Inj 250 mcg</u>	241	\$4,270	\$17.7180		C H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Tetracosactrin</b>						
<u>Inj 1 mg per ml, 1 ml</u>	107	\$2,876	\$26.8800	C H	1%	
<b>Thiamine Hydrochloride</b>						
Inj 100 mg per ml, 2 ml				H	1%	A combination product would be considered
<b>Thioguanine</b>						
Tab 40 mg	6,913	\$26,867	\$3.8864	C H PCT	1%	
<b>Thiotepa</b>						
Inj 15 mg				H PCT	1%	
<b>Tiaprofenic Acid</b>						
Tab 300 mg	101,127	\$6,792	\$0.0672 *	C H	1%	
<b>Timolol Maleate</b>						
<u>Eye drops 0.25%</u>	116,643	\$55,289	\$0.4740	C		
<u>Eye drops 0.5%</u>	150,958	\$69,139	\$0.4580	C		
<b>Tobramycin</b>						
Eye drops 0.3%	4,973	\$11,418	\$2.2960	C H	1%	
Eye oint 0.3%	2,191	\$6,542	\$2.9857	C H	1%	
Inj 40 mg per ml, 2 ml	35,632	\$245,861	\$6.9000	C H	1%	
<b>Tolcapone</b>						
Tab 100 mg	97,352	\$125,341	\$1.2875	C H	1%	
<b>Tramadol Hydrochloride</b>						
<u>Cap 50 mg</u>			\$0.0695	C H	1%	This was recently listed on the Pharmaceutical Schedule
Inj 50 mg per ml, 1 ml				H	1%	
Inj 50 mg per ml, 2 ml				H	1%	
Oral liq 100 mg per ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab sustained release 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab sustained release 100 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab sustained release 150 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab sustained release 200 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab sustained release 300 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab sustained release 400 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Triamcinolone Acetonide</b>						
<u>0.1% in Dental Paste USP</u>	104,623	\$91,650	\$0.8760	C H	1%	
<u>Crn 0.02%</u>	590,476	\$39,149	\$0.0663	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Triamcinolone Acetonide</b>						
Inj 10 mg per ml, 1 ml	5,421	\$12,045	\$2.2220	C H	1%	
<u>Inj 40 mg per ml, 1 ml</u>	59,596	\$334,810	\$5.6180	C H	1%	
<u>Oint 0.02%</u>	303,137	\$20,280	\$0.0669	C H	1%	
<b>Trimethoprim</b>						
Oral liq				C H	1%	Not currently listed on the Pharmaceutical Schedule
<u>Tab 300 mg</u>	1,356,144	\$235,698	\$0.1738	C H	1%	
<b>Tropicamide</b>						
Eye drops 0.5%	1,238	\$590	\$0.4767	C H	1%	Single dose presentation would not be a DV Pharmaceutical
Eye drops 1%	3,316	\$1,914	\$0.5773	C H	1%	Single dose presentation would not be a DV Pharmaceutical
<b>Tyloxapol</b>						
Eye drops 0.25%	6,383	\$3,672	\$0.5753	C		
<b>Ursodeoxycholic Acid</b>						
<u>Cap 250 mg - 300 mg</u>	377,811	\$676,282	\$1.7900	C H	1%	
<b>Vancomycin Hydrochloride</b>						
<u>Inj 50 mg per ml, 10 ml</u>	2,079	\$10,478	\$5.0400	C H	1%	
<b>Verapamil Hydrochloride</b>						
Tab 40 mg	252,548	\$17,704	\$0.0701	C H	1%	
Tab 80 mg	204,040	\$23,954	\$0.1174	C H	1%	
Tab long-acting 120 mg	2,010,790	\$122,256	\$0.0608	C H	1%	
Tab long-acting 240 mg	1,693,804	\$169,380	\$0.1000	C H	1%	
<b>Zidovudine (AZT) with Lamivudine</b>						
Tab 300 mg with lamivudine 150 mg	240,310	\$2,672,247	\$11.1200	+ C H	1%	
<b>Zinc and Castor Oil</b>						
Oint BP (pack size 30 g or less)				H	1%	
<u>Oint BP (pack size greater than 30 g)</u>	12,347,672	\$126,193	\$0.0102	C		
<b>Zinc Sulphate</b>						
Cap 50 mg elemental				C H	1%	
<b>Ziprasidone</b>						
Cap 20 mg	166,956	\$244,535	\$1.4647	C H	1%	
Cap 40 mg	153,865	\$422,565	\$2.7463	C H	1%	
Cap 60 mg	24,525	\$101,031	\$4.1195	C H	1%	
Cap 80 mg	44,665	\$245,330	\$5.4927	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>	
<b>Zolmitriptan</b>						
Tab 2.5 mg				C	Not currently listed on the Pharmaceutical Schedule	
Tab 5 mg				C	Not currently listed on the Pharmaceutical Schedule	
<b>Zopiclone</b>						
<u>Tab 7.5 mg</u>	16,827,035	\$707,409	\$0.0420	C H	1%	